Haemonetics (STU:HAZ) Debt-to-Asset : 0.37 (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Haemonetics Debt-to-Asset?

Haemonetics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €9 Mil. Haemonetics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €734 Mil. Haemonetics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was €2,020 Mil. Haemonetics's debt to asset for the quarter that ended in Mar. 2024 was 0.37.

Haemonetics Debt-to-Asset Historical Data

The historical data trend for Haemonetics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Haemonetics Debt-to-Asset Chart

Haemonetics Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Debt-to-Asset

Get a 7-Day Free Trial

0.35

0.39

0.42

0.40

0.37

Haemonetics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Asset	Get a 7-Day Free Trial															0.40	0.39	0.38	0.40	0.37

Competitive Comparison of Haemonetics's Debt-to-Asset

For the Medical Instruments & Supplies subindustry, Haemonetics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Haemonetics's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Haemonetics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Haemonetics's Debt-to-Asset falls into.

Haemonetics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Haemonetics's Debt-to-Asset for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(9.411	+	733.759)	/	2019.944
	=	0.37

Haemonetics's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(9.411	+	733.759)	/	2019.944
	=	0.37

Haemonetics (STU:HAZ) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Haemonetics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Haemonetics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Haemonetics (STU:HAZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Haemonetics Corp (STU:HAZ) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

HAE:USA

Address

125 Summer Street, Boston, MA, USA, 02110

Website

https://www.haemonetics.com

Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company places primary emphasis on its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.

Haemonetics (STU:HAZ) Headlines

No Headlines